Breakfast Symposium: Considering Heart Rate in Cardiovascular Disease: A Focus on Heart Failure

Co-Chairs:
Joseph S. Alpert, MD - Sarver Heart Center - University of Arizona College of Medicine
Robin J Trupp, RN, PhD, ACNP-BC, CHFN, FAHA - University of Illinois at Chicago

Description
Dr. Alpert will review epidemiology/pathophysiology of heart failure, summarize morbidity/mortality data associated with heart rate and discuss mechanisms which regulate heart rate. Dr. Trupp will discuss a case study and use ACC/AHA recommended Risk Scores to predict outcome in heart failure patients.

Supported by Amgen

Product Theater: The Latest Technology Innovations to Improve the Delivery of Sleep Apnea Therapy - PART 1

Speakers: Robin J. Trupp PhD, ACNP-BC, CHFN, Kim D’Ambra - Clinical Manager

Program Description:
Patient adherence to continuous positive airway pressure (CPAP) therapies has always been challenging.  This product theater will use an interactive, hands-on format to demonstrate technological advancements targeting the delivery of sleep therapy and enhancing adherence.

Program Objectives:

• Explain the differences between AutoPAP, Bilevel and ASV
• Explain how different sleep disorders may affect therapy selection
• Provide trouble-shooting tips to enhance adherence
• Samples of the newest masks will be given away to 25 randomly selected attendees

Supported by ResMed

Product Theater: Diminishing Perspectives: An Exploration of the Challenges Faced by a Patient With Heart Failure

Speaker: Robin J Trupp, RN, PhD, ACNP-BC, CHFN, FAHA
Adjunct Assistant Clinical Professor
University of Illinois at Chicago, School of Nursing

Program Description:
Please join us for a detailed discussion focusing on a patient and his family, as they grapple with challenges in our new film “Diminishing Perspectives.” Patients suffering from heart failure and their families face a multitude of challenges on a daily basis, not only with the management of multiple medications, but also with attempting to incorporate new lifestyle changes into their daily routine. Following hospitalization for heart failure, patients often face uncertainty regarding their ability to resume a normal life. Considerable opportunity exists for heart failure nurses to assist patients in overcoming challenges and achieving guideline and dietary compliance.

Program Objectives:

Understand the various challenges faced by patients with heart failure
Identify opportunities for heart failure nurses to assist patients in overcoming these challenges and achieving guideline and dietary compliance
 

Supported by Novartis

Dinner Symposium: The Evolving Role of Hemodynamics and Pressure-Guided Therapy for Heart Failure Management

Faculty: 
Sara Paul, RN, DNP, FNP, FAHA, Moderator
Philip B.  Adamson, MD, MSc, FACC, Chair
JoAnn Lindenfeld, MD, FACC

This activity has been designed to meet the educational needs of registered nurses, nurse practitioners, and other health care professionals involved in the care of patients with heart failure. Participants must be registered for the AAHFN 10th Annual Conference; there is no additional fee for this symposium.

Objectives After completing this activity, the participant should be better able to:

1. Describe potential data elements available from current heart failure technology.
2. Explain the rationale for measuring & utilizing pulmonary artery pressure to guide patient therapy.
3. Identify patient characteristics and clinical outcomes reported in the CHAMPION clinical trial.
4. Utilize changes in heart failure diagnostic data to predict clinical events.
5. Identify barriers in clinical practice to the practical integration of device data.
6. Integrate device data into the everyday management of heart failure patients.
7. Provide appropriate care and counsel for heart failure patients and their families.

Agenda:
7:00 pm Registration and Reception, Dinner Seating
7:30 pm Welcome & Introduction Sara Paul, RN, DNP, FNP, FAHA
7:40 pm Advances in Pulmonary Artery Pressure-Guided Heart Failure Management: Rationale and Strategies JoAnn Lindenfeld, MD, FACC
8:00 pm Clinical Research Updates from the CHAMPION Trial Philip B. Adamson, MD, MSc, FACC
8:20 pm Integration of PA Pressure-Guided HF Management into Clinical Practice: Challenges & Practical Applications JoAnn LIndenfeld and Philip B. Adamson
8:30pm Case Scenarios with Panel Discussion and Q&A All
9:00 pm Adjourn

Credit Designation This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.
Accreditation Statement Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

California Board of Registered Nursing Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.5 contact hours. 

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks.

Co-provided by:  Postgraduate Institute for Medicine and Saterdalen & Associates

Credit Designation:
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

This session is supported by an educational grant from St. Jude Medical, Inc.

Breakfast Symposium: Matters of the Heart - Caring for your African American HF Patients

Faculty:
Jerome A. Robinson, MD, FACC, FACP, FASH, FSCAI
• Member of AMA, NMA, ACC, ACP, ISHIB, ASH, SCAI, and ABC
• Practicing clinical and interventional cardiologist in San Diego, California
• Recognized hypertension specialist
• Participated in numerous clinical trials over the past 25 years in various aspects of
cardiovascular disease including interventional trials and ARIES

Lisa Alvarez, FNP-BC, RN, MSN
• Member of CANP, AANP, AHA, ACC
• Practices in the cardiology/cardiothoracic surgery department at Sharp Hospital,
Chula Vista, CA
• Consulting/practicing at the Cardiovascular Institute of San Diego

There is a Heart Failure (HF) epidemic going on worldwide and nationally. It is one of the few
cardiovascular disorders on the rise. According to the World Health Organization (WHO), there are over 23 million cases of HF worldwide and 6 million in the US alone. In the US, there are an estimated  670,000 new cases of HF diagnosed annually. This condition is a major cause of morbidity and mortality. It is the leading cause of hospitalizations of the elderly in the US. There are over 1 million hospitalizations annually and over 50% of these patients are readmitted within 6 months of discharge.

Heart failure is the single largest expense for Medicare costing over $32 billion annually.
Despite the risks of cardiovascular disease, including heart failure in African Americans, some guideline indicated therapies are disproportionately underused in this population. Heart failure studies have demonstrated that treatment guidelines are adopted slowly, are applied inconsistently, and as a result, often fail to lead to improvements in patient care and outcomes. ACC/AHA practice guidelines give a class 1 recommendation for the use of H-ISDN in self-identified black patients with symptomatic systolic heart failure on optimal therapy. In the 2010 HFSA practice guidelines, a combination of hydralazine and isosorbide dinitrate was recommended as part of standard therapy in addition to beta blockers and ACE inhibitors for African Americans with HF and reduced LVET. Yet, a recent study indicated that only 7.3% of eligible black patients are actually receiving H-ISDN. A registry of hospitalized HF patients showed only 4.5% of blacks and 2.6% of whites went home on I-SDN. Establishing educational initiatives should help to reduce practice variability, eliminate gaps between guidelines and practice, and improve the outcome of patients with HF.

This activity is co-provided by Arbor Pharmaceuticals LLC and AAHFN

Speakers: Robin J. Trupp PhD, ACNP-BC, CHFN, Kim D’Ambra - Clinical Manager

Program Description:
Patient adherence to continuous positive airway pressure (CPAP) therapies has always been challenging.  This product theater will use an interactive, hands-on format to demonstrate technological advancements targeting the delivery of sleep therapy and enhancing adherence.

Program Objectives:

Explain the differences between AutoPAP, Bilevel and ASV
Explain how different sleep disorders may affect therapy selection
Provide trouble-shooting tips to enhance adherence
Samples of the newest masks will be given away to 25 randomly selected attendees

Supported by ResMed

Speaker: Dr. Marc Silver

Supported by Medtronic

Description: Management of patients with PAH requires a holistic, multidisciplinary effort. Nurses working in the fields of pulmonology, cardiology, rheumatology, and intensive care should have a clear understanding of the diagnostic criteria, quality-of-life issues, and medical management considerations for patients diagnosed with PAH. Issues for nurses include early identification and referral of patients with symptoms suggestive of PAH for appropriate diagnostic testing, understanding the risk-benefit equation for specific PAH therapies and associated treatments, and nursing methods of support in crucial clinical management roles to improve patient quality of life and medical outcomes.

Supported by independent education grants from Gilead Sciences Medical Affairs, United Therapeutics Corporation and its subsidiary, Lung Biotechnology. Co-provided for CME credit by the University of Nebraska Medical Center and Practice Point Communications.

Product Theater: Closing the Gap on Thrombotic Events

Speaker: Alan K. Jacobson, MD, FACC
Assistant Professor of Medicine
Loma Linda University School of Medicine
Director, Anticoagulation Services
Veterans Affairs Medical Center
Loma Linda, California

Program Description: This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

Supported by Janssen Pharmaceuticals, Inc
This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communication about its medicines.